532 related articles for article (PubMed ID: 29330358)
21. The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.
Tsubaki M; Seki S; Takeda T; Chihara A; Arai Y; Morii Y; Imano M; Satou T; Shimomura K; Nishida S
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114380
[TBL] [Abstract][Full Text] [Related]
22. Tumor-host cell interactions in the bone disease of myeloma.
Fowler JA; Edwards CM; Croucher PI
Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
[TBL] [Abstract][Full Text] [Related]
23. N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation.
Groen RW; de Rooij MF; Kocemba KA; Reijmers RM; de Haan-Kramer A; Overdijk MB; Aalders L; Rozemuller H; Martens AC; Bergsagel PL; Kersten MJ; Pals ST; Spaargaren M
Haematologica; 2011 Nov; 96(11):1653-61. PubMed ID: 21828122
[TBL] [Abstract][Full Text] [Related]
24. Myeloma bone disease.
Sezer O
Hematology; 2005; 10 Suppl 1():19-24. PubMed ID: 16188625
[TBL] [Abstract][Full Text] [Related]
25. Why do myeloma patients have bone disease? A historical perspective.
Børset M; Sundan A; Waage A; Standal T
Blood Rev; 2020 May; 41():100646. PubMed ID: 31810754
[TBL] [Abstract][Full Text] [Related]
26. Pathogenesis of myeloma bone disease.
Roodman GD
Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
[TBL] [Abstract][Full Text] [Related]
27. Osteoblastogenesis and tumor growth in myeloma.
Yaccoby S
Leuk Lymphoma; 2010 Feb; 51(2):213-20. PubMed ID: 20038269
[TBL] [Abstract][Full Text] [Related]
28. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.
Fu J; Li S; Feng R; Ma H; Sabeh F; Roodman GD; Wang J; Robinson S; Guo XE; Lund T; Normolle D; Mapara MY; Weiss SJ; Lentzsch S
J Clin Invest; 2016 May; 126(5):1759-72. PubMed ID: 27043283
[TBL] [Abstract][Full Text] [Related]
30. Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Leuk Lymphoma; 2014 Apr; 55(4):911-9. PubMed ID: 23915193
[TBL] [Abstract][Full Text] [Related]
31. New insights in myeloma-induced osteolysis.
Barillé-Nion S; Bataille R
Leuk Lymphoma; 2003 Sep; 44(9):1463-7. PubMed ID: 14565645
[TBL] [Abstract][Full Text] [Related]
32. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease.
Hjertner O; Torgersen ML; Seidel C; Hjorth-Hansen H; Waage A; Børset M; Sundan A
Blood; 1999 Dec; 94(11):3883-8. PubMed ID: 10572104
[TBL] [Abstract][Full Text] [Related]
33. Role of osteoblast suppression in multiple myeloma.
Stewart JP; Shaughnessy JD
J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324
[TBL] [Abstract][Full Text] [Related]
34. Myeloma and Bone Disease.
Panaroni C; Yee AJ; Raje NS
Curr Osteoporos Rep; 2017 Oct; 15(5):483-498. PubMed ID: 28861842
[TBL] [Abstract][Full Text] [Related]
35. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
36. Blockade of XCL1/Lymphotactin Ameliorates Severity of Periprosthetic Osteolysis Triggered by Polyethylene-Particles.
Tian Y; Terkawi MA; Onodera T; Alhasan H; Matsumae G; Takahashi D; Hamasaki M; Ebata T; Aly MK; Kida H; Shimizu T; Uetsuki K; Kadoya K; Iwasaki N
Front Immunol; 2020; 11():1720. PubMed ID: 32849609
[TBL] [Abstract][Full Text] [Related]
37. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
[TBL] [Abstract][Full Text] [Related]
38. [Myeloma bone disease and RANKL signaling].
Abe M
Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
[TBL] [Abstract][Full Text] [Related]
39. A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function.
Vallet S; Pozzi S; Patel K; Vaghela N; Fulciniti MT; Veiby P; Hideshima T; Santo L; Cirstea D; Scadden DT; Anderson KC; Raje N
Leukemia; 2011 Jul; 25(7):1174-81. PubMed ID: 21403648
[TBL] [Abstract][Full Text] [Related]
40. Gene silencing of the BDNF/TrkB axis in multiple myeloma blocks bone destruction and tumor burden in vitro and in vivo.
Ai LS; Sun CY; Wang YD; Zhang L; Chu ZB; Qin Y; Gao F; Yan H; Guo T; Chen L; Yang D; Hu Y
Int J Cancer; 2013 Sep; 133(5):1074-84. PubMed ID: 23420490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
